[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysfunctional-av-graft\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysfunctional-av-graft":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100568927","serranator-point-force-registry-100568927",false,"NCT06687590","Serranator POINT FORCE Registry","POst-Market ClINical Follow-up STudy oF the SerranatOR PTA Serration Balloon CathEter","POINT FORCE","Inclusion Criteria:\n\n* Subjects intended to be treated with Serranator® for de-novo or restenotic lesions of the iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries or dysfunctional native or synthetic arteriovenous dialysis fistulae.\n* Subjects presenting with claudication or critical limb-threatening ischemia (CLTI) by Rutherford Clinical Category 3, 4, 5, or 6 of the target limb.\n* Age of subject is \\> 18.\n* Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.\n\nExclusion Criteria:\n\n* Subjects with any medical condition that would make him\u002Fher an inappropriate candidate for treatment with Serranator® as per Instructions for Use (IFU) or investigator's opinion.\n* Subject already enrolled in other investigational (interventional) studies that would interfere with study endpoints.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","1 Day","OBSERVATIONAL","The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario.\n\nThe data and conclusions derived from this study will be used to provide clinical evidence for the clinical evaluation process.",[26,27,28],"Peripheral Artery Disease (PAD)","Dysfunctional AV Fistula","Dysfunctional AV Graft","RECRUITING","2026-05-01",{"date":32,"type":33},"2026-05-07","ACTUAL",{"date":35,"type":33},"2025-01-22",{"date":37,"type":21},"2026-08-31",{"name":39,"class":40},"Cagent Vascular LLC","INDUSTRY",19]